4995 Murphy Canyon Road
Suite 300
San Diego, CA 92123
United States
760 471 8536
https://www.conduitpharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 7
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. David Joszef Tapolczay | CEO & Director | 419,8k | N/A | 1959 |
Mr. Adam Sragovicz | Chief Financial Officer | 116,67k | N/A | 1970 |
Dr. Joanne M. Holland | Chief Scientific Officer | N/A | N/A | 1975 |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.